BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extends to patients with acute myeloid leukemia (AML). The data, presented at the 50th Annual Meeting of the American Society of Hematology (ASH), reported that patients with WHO-defined AML who were treated with VIDAZA (azacitidine) achieved significantly improved overall survival compared to those treated with a conventional care regimen (CCR).
